Fig. 5

In vitro anticancer activity of fabricated nanoparticles. (A) Cell viability of MOLM-13 cells treated with different formulations for 48 h (n = 3). (B) Cell viability of HCT116 cells treated with different formulations for 48 h (n = 3). (C) Apoptotic assays of MOLM-13 cells treated with different formulations (n = 3). (D) Western blot assay of CDK-4 in MOLM13 and HCT116 cells treated with NP, 2.3%A6-NP and 5.5%A6-NP, respectively.   ^*p < 0.05, ^**p < 0.01, ^***p < 0.001